动态磁敏感对比与扩散MR成像根据2016年WHO脑肿瘤分类识别少突胶质细胞瘤:直方图分析方法
回顾性分析71例未经治疗的WHO II级和III级弥漫性浸润性胶质瘤成人患者,基于全肿瘤体积直方图计算rCBV和ADC参数,评估其区分少突胶质细胞瘤与星形细胞瘤的价值。少突胶质细胞瘤较星形细胞瘤显示更高的微血管密度(rCBVMean≥0.80,p=0.013)和更高的血管异质性(rCBVPeak≤0.044,p=0.015),且细胞密度更高(ADCMean≤1094×10⁻⁶ mm²/s,p=0.009)。直方图分析的rCBV和ADC参数可能作为识别少突胶质细胞瘤的生物标志物。
要点
- 少突胶质细胞瘤rCBVMean≥0.80(p=0.013)和rCBVPeak≤0.044(p=0.015)提示更高微血管密度和血管异质性。
- ADCMean≤1094×10⁻⁶ mm²/s(p=0.009)的弥漫性胶质瘤更可能为少突胶质细胞瘤。
- rCBV和ADC直方图分析可区分WHO II级弥漫性星形细胞瘤与III级间变性星形细胞瘤。
核心结论
- 直方图衍生的rCBV和ADC参数可能作为识别少突胶质细胞瘤的生物标志物,并可能有助于基于遗传特征表征弥漫性胶质瘤。
研究设计与样本
- 回顾性识别并分析71例未经治疗的WHO II级和III级弥漫性浸润性胶质瘤成人患者,基于全肿瘤体积直方图计算rCBV和ADC参数。
诊断标准与关键数值
- 少突胶质细胞瘤较星形细胞瘤显示更高的rCBVMean(≥0.80,p=0.013)。
- 少突胶质细胞瘤较星形细胞瘤显示更高的血管异质性(rCBVPeak≤0.044,p=0.015)。
- ADCMean≤1094×10⁻⁶ mm²/s(p=0.009)的弥漫性胶质瘤更可能为少突胶质细胞瘤。
- 直方图分析的rCBV和ADC参数可区分WHO II级弥漫性星形细胞瘤与WHO III级间变性星形细胞瘤。
临床应用与阅片要点
- 作者认为直方图衍生的rCBV和ADC参数可能作为识别少突胶质细胞瘤的生物标志物。
- 作者认为上述参数可能有助于基于遗传特征表征弥漫性胶质瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: According to the revised World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) of 2016, oligodendrogliomas are now defined primarily by a specific molecular signature (presence of IDH mutation and 1p19q codeletion). The purpose of our study was to assess the value of dynamic susceptibility contrast MR imaging (DSC-MRI) and diffusion-weighted imaging (DWI) to characterize oligodendrogliomas and to distinguish them from astrocytomas.
METHODS: Seventy-one adult patients with untreated WHO grade II and grade III diffuse infiltrating gliomas and known 1p/19q codeletion status were retrospectively identified and analyzed using relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) maps based on whole-tumor volume histograms. The Mann-Whitney U test and logistic regression were used to assess the ability of rCBV and ADC to differentiate between oligodendrogliomas and astrocytomas both independently, but also related to the WHO grade. Prediction performance was evaluated in leave-one-out cross-validation (LOOCV).
RESULTS: Oligodendrogliomas showed significantly higher microvascularity (higher rCBVMean ≥ 0.80, p = 0.013) and higher vascular heterogeneity (lower rCBVPeak ≤ 0.044, p = 0.015) than astrocytomas. Diffuse gliomas with higher cellular density (lower ADCMean ≤ 1094 × 10-6 mm2/s, p = 0.009) were more likely to be oligodendrogliomas than astrocytomas. Histogram analysis of rCBV and ADC was able to differentiate between diffuse astrocytomas (WHO grade II) and anaplastic astrocytomas (WHO grade III).
CONCLUSION: Histogram-derived rCBV and ADC parameter may be used as biomarkers for identification of oligodendrogliomas and may help characterize diffuse gliomas based upon their genetic characteristics.
引用
- Latysheva A, Emblem KE, Brandal P, et al. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach. Neuroradiology. 2019. PMID: 30712139. doi:10.1007/s00234-019-02173-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。